Literature DB >> 33681512

Coronary Lesions and Systemic Inflammatory Response Syndrome in Kawasaki Disease.

Yutaro Tomobe1, Osamu Nomura2, Yoshihiko Morikawa3, Nobuaki Inoue2, Hiroshi Sakakibara1, Masaru Miura3,4.   

Abstract

INTRODUCTION: In patients with Kawasaki disease (KD), who later develop coronary artery lesions (CALs), several inflammatory cytokines are reportedly higher than in patients without CALs. Systemic inflammatory response syndrome (SIRS) is used as a clinical index of hypercytokinemia. The objective of this study was to determine whether SIRS is related to CAL formation.
METHODS: We conducted a retrospective cohort study of KD patients admitted to our hospital between July 2012 and July 2015. The subjects were classified into the SIRS or the non-SIRS group based on their vital signs and blood test results. Their initial treatment was determined by their Kobayashi score. We compared the incidence of CALs between the two groups.
RESULTS: Of 357 KD patients, 277 were included in this study and 175 (63.2%) met the SIRS criteria. The incidence of CAL formation at week 1 in the clinical course and at one month after the primary treatment was significantly higher in the SIRS group than in the non-SIRS group (17.7% vs. 7.8%, p = 0.03 and 10.9% vs. 3.9%, p = 0.03, respectively). Multivariate analyses showed that after adjusting for each variable of the Kobayashi score, SIRS was an independent risk factor for CAL formation at week 1 in the clinical course (odds ratio, 2.7; 95% confidence interval, 1.03-7.23; p = 0.04).
CONCLUSIONS: SIRS can be a risk factor for CAL in the acute phase of KD.
Copyright © Japan Medical Association.

Entities:  

Keywords:  Kawasaki disease; Kobayashi score; coronary artery lesion; systemic inflammatory response syndrome; vital signs

Year:  2018        PMID: 33681512      PMCID: PMC7930751          DOI: 10.31662/jmaj.2018-0013

Source DB:  PubMed          Journal:  JMA J        ISSN: 2433-328X


  27 in total

1.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

2.  Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition).

Authors:  Mamoru Ayusawa; Tomoyoshi Sonobe; Shigeru Uemura; Shunnichi Ogawa; Yoshikazu Nakamura; Nobuyuki Kiyosawa; Masahiro Ishii; Kensuke Harada
Journal:  Pediatr Int       Date:  2005-04       Impact factor: 1.524

3.  Scoring system for the prediction of severe acute pancreatitis in children.

Authors:  Mitsuyoshi Suzuki; Nobutomo Saito; Nakayuki Naritaka; Satoshi Nakano; Kei Minowa; Yuka Honda; Yoshikazu Ohtsuka; Atsuyuki Yamataka; Toshiaki Shimizu
Journal:  Pediatr Int       Date:  2014-11-25       Impact factor: 1.524

4.  Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.

Authors:  Lynn A Sleeper; L Luann Minich; Brian M McCrindle; Jennifer S Li; Wilbert Mason; Steven D Colan; Andrew M Atz; Beth F Printz; Annette Baker; Victoria L Vetter; Jane W Newburger
Journal:  J Pediatr       Date:  2010-12-18       Impact factor: 4.406

5.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Circulation       Date:  2004-10-26       Impact factor: 29.690

Review 6.  Kawasaki disease. With particular emphasis on arterial lesions.

Authors:  S Naoe; K Takahashi; H Masuda; N Tanaka
Journal:  Acta Pathol Jpn       Date:  1991-11

7.  Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.

Authors:  Yujia Wang; Wei Wang; Fangqi Gong; Songling Fu; Qing Zhang; Jian Hu; Yanqi Qi; Chunhong Xie; Yiying Zhang
Journal:  Arthritis Rheum       Date:  2013-03

8.  Clinical manifestations of Kawasaki disease shock syndrome: a case-control study.

Authors:  Pei-Shin Chen; Hsin Chi; Fu-Yuan Huang; Chun-Chih Peng; Ming-Ren Chen; Nan-Chang Chiu
Journal:  J Microbiol Immunol Infect       Date:  2013-08-06       Impact factor: 4.399

Review 9.  Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.

Authors:  Shaojie Chen; Ying Dong; Yuehui Yin; Mitchell W Krucoff
Journal:  Heart       Date:  2012-08-06       Impact factor: 5.994

Review 10.  Kawasaki syndrome.

Authors:  Jane C Burns; Mary P Glodé
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.